Heart Test Laboratories (NASDAQ:HSCS) vs. Pathfinder Cell Therapy (OTCMKTS:PFND) Head to Head Review

Pathfinder Cell Therapy (OTCMKTS:PFND) and Heart Test Laboratories (NASDAQ:HSCS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Profitability

This table compares Pathfinder Cell Therapy and Heart Test Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
Heart Test Laboratories	N/A	-144.12%	-94.48%

Analyst Ratings

This is a summary of current recommendations for Pathfinder Cell Therapy and Heart Test Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
Heart Test Laboratories	0	0	2	0	3.00

Heart Test Laboratories has a consensus target price of $13.50, suggesting a potential upside of 294.74%. Given Heart Test Laboratories’ stronger consensus rating and higher probable upside, analysts clearly believe Heart Test Laboratories is more favorable than Pathfinder Cell Therapy.

Insider & Institutional Ownership

17.2% of Heart Test Laboratories shares are held by institutional investors. 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Comparatively, 1.8% of Heart Test Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Pathfinder Cell Therapy and Heart Test Laboratories”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
Heart Test Laboratories	$14,700.00	212.41	-$6.61 million	($7.91)	-0.43

Pathfinder Cell Therapy has higher earnings, but lower revenue than Heart Test Laboratories.

Summary

Heart Test Laboratories beats Pathfinder Cell Therapy on 5 of the 8 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About Heart Test Laboratories

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.